| Symbol
| MCL1
| contributors: mct/shn - updated : 08-12-2017
|
| HGNC name
| myeloid cell leukemia sequence 1 (BCL2-related)
|
| HGNC id
| 6943
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in NPM-ALK positive anaplastic large cells lymphoma | | tumoral
|
|
| --over
|
|
in rhabdomyosarcoma  | | tumoral
|
|
| --over
|
| |
in severalhaematological cancers and solid tumours, including chronic myeloid leukemia and hepatocellular carcinoma | |
Variant & Polymorphism
| 
| |
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | hemopathy | | |
| attractive target and survival factor in neoplastic mast cells in systemic mastocytosis | | cancer | | | |
| attractive and potential therapeutic target in a number
of malignancies | | cancer | hemopathy | | |
| potential target in germinal center-derived lymphomas that do not overexpress BCL2L1 |
| | | |
|
| Deletion of Mcl-1 resulted in peri-implantation embryonic lethality in mouse ( | |
mice conditional for Mcl-1 display a profound reduction in B and T lymphocytes when MCL-1 is removed, deletion of Mcl-1 during early lymphocyte differentiation increased apoptosis and arrested the development at pro-B-cell and double-negative T-cell stages ( |
|
deletion of Mcl-1 in cortical neurons of transgenic mice activates a robust autophagic response |